Scottish angel investment syndicate Archangels has announced that it helped channel £17.9 million into early-stage technology and life sciences companies during the first six months of 2026, reinforcing its role as a key source of funding for Scotland’s innovation ecosystem.
The investment total was achieved through a combination of direct contributions from Archangels’ investor network and significant backing from co-investment partners, allowing several high-potential startups to secure the capital needed for expansion and commercialization.
Direct Investments and Co-Investment Drive Funding Growth
Of the £17.9 million raised during the period, £7.2 million came directly from members of Archangels, while an additional £10.7 million was secured through co-investment from partner organizations and investors.
The collaborative funding model enabled multiple businesses to complete investment rounds aimed at accelerating research, product development, manufacturing, and international market expansion.
Biocaptiva Advances Cancer Diagnostic Technology
Among the companies supported was Biocaptiva, a University of Edinburgh spin-out that secured £1.58 million to advance commercialization of its proprietary msX platform.
The technology is designed to extract cell-free DNA directly from whole blood samples without the need for centrifuges or additional laboratory reagents, making liquid biopsy preparation for cancer research and diagnostic testing faster, more reliable, and easier to scale.
Alongside the funding, the company has also introduced its first commercial product to the United States market, marking an important milestone in its international growth strategy.
Bioliberty Expands AI-Powered Rehabilitation Platform
Another major investment involved Bioliberty, another University of Edinburgh spin-out, which completed a £6.2 million Series A funding round led by the Scottish National Investment Bank.
Archangels participated in the round alongside investors including Eos Advisory, Old College Capital, Hanna Capital SEZC, and new investor Conduit Connect.
The financing forms part of £7.7 million ($10.5 million) raised by the company over the past ten months.
The fresh capital will support continued product development, expanded manufacturing operations in Scotland, and further commercial growth in the United States, where Bioliberty’s AI-powered soft robotic wearable rehabilitation technology is already being used in several leading rehabilitation centers.
More Than Three Decades Supporting Innovation
Established in 1992, Archangels connects experienced private investors with emerging Scottish companies developing technologies in sectors including life sciences and advanced technology.
The syndicate evaluates investment opportunities through detailed due diligence before presenting them to members, helping startups secure both capital and strategic guidance during critical stages of growth.
Long-Term Economic Impact Across Scotland
Over more than three decades, Archangels has grown into one of Scotland’s largest angel investment syndicates, with approximately 120 members, a 12-member board and executive leadership team, and a portfolio of more than 20 companies.
The organization has invested close to £200 million in early-stage businesses, contributing to the creation of roughly 5,000 jobs while generating an estimated £1.5 billion in economic value for Scotland.
Its investment track record also includes supporting 26 portfolio companies through successful exits, producing gross shareholder returns exceeding £400 million.
What’s Next?
With strong investment momentum in the first half of 2026, Archangels is expected to continue backing innovative Scottish startups seeking funding for commercialization, international expansion, and technological development.
The syndicate’s ongoing collaboration with institutional and private co-investors is likely to remain a key driver of Scotland’s early-stage technology and life sciences sector.
Summary
Archangels leveraged £17.9 million in funding for Scottish early-stage technology and life science companies during the first half of 2026, combining £7.2 million from its members with £10.7 million from co-investors.
The funding supported companies including Biocaptiva, which is commercializing cancer diagnostic technology, and Bioliberty, which is expanding its AI-powered rehabilitation platform.
Since its founding in 1992, Archangels has invested nearly £200 million, helped create around 5,000 jobs, and generated an estimated £1.5 billion in economic value across Scotland.
